Discovery of a Novel Covalent EZH2 Inhibitor Based on Tazemetostat Scaffold for the Treatment of Ovarian Cancer
Qiangsheng Zhang(Sichuan University), Luoting Yu(State Key Laboratory of Biotherapy), Guoquan Wan(Sichuan University), Ningyu Wang(Southwest Jiaotong University), Hongling Yang(Sichuan University), Jiaying Cao(Sichuan University), Hongtao Xiao(University of Electronic Science and Technology of China), Zhihao Liu(Sichuan University), Xinyi Chen(Sichuan University), Yongxia Zhu(University of Electronic Science and Technology of China), Qiang Feng(École Polytechnique Fédérale de Lausanne), Shuyan Zhou(Sichuan University), Wan Seok Yang(Columbia University)
Cited by 24
Related Papers
Peroxidation of polyunsaturated fatty acids by lipoxygenases drives ferroptosis
|Proceedings of the National Academy of Sciences|2016|2.3k
miRTarBase update 2022: an informative resource for experimentally validated miRNA–target interactions
|Nucleic Acids Research|2021|1k
The Anthelmintic Drug Niclosamide Induces Apoptosis, Impairs Metastasis and Reduces Immunosuppressive Cells in Breast Cancer Model
|PLoS ONE|2014|131
Design and Synthesis of EZH2-Based PROTACs to Degrade the PRC2 Complex for Targeting the Noncatalytic Activity of EZH2
|Journal of Medicinal Chemistry|2021|116
Language Models of Code are Few-Shot Commonsense Learners
|Unknown|2022|106